All In Biotech

Drug Trial Radar · NCT07891910

Iopidine to Decrease Intraocular Pressure Rise After Injections

Effect of Pre-Injection Iopidine on Intraocular Pressure and Transient Vision Loss Following High-Volume Intravitreal Injections

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Dec 1, 2026

Study completion Jan 1, 2027

Sponsor

Lead sponsor
Retina Consultants of DelmarvaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, controlled, open-label, single-site investigator-initiated clinical trial. A total of 120 participants will be randomized in a 1:1 ratio either to receive one drop of apraclonidine 1% ophthalmic solution (Iopidine) approximately 20-30 minutes before a clinically indicated intravitreal injection of Eylea HD or Syfovre, or to a control group that will receive no pre-injection study medication. The intravitreal injection is part of the participant's routine clinical care. The research-specific intervention for participants assigned to the Iopidine group is administration of Iopidine. Participants assigned to the control group will receive no pre-injection study medication. Both groups will undergo post-injection IOP assessments at 5, 15, and 30 minutes post-injection and transient-vision-loss assessments.

Conditions

  • Macular Degeneration
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Glaucoma

Interventions

  • Apraclonidine 1.0% ophthalmic solutionDrug

    One drop prior to intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular pressure one minute after injectionTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Retina Consultants of Delmarva

    Easton, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.